Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Immunotherapy Targeting Sarcomas
NCT04433221Phase 2Not yet recruiting
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jul 2027
- Primary completion
- May 2029
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in sarcoma, osteosarcoma (OS) and Ewing sarcoma, sponsored by Shenzhen Geno-Immune Medical Institute. Primary endpoint: Safety of CART cells infusion at 3 months. Planned start Jul 2027; status: not yet recruiting.
02
Conditions
sarcomaosteosarcoma (OS)Ewing sarcoma
Beyond the preview
Go deeper on NCT04433221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04433221.